Emcure Pharmaceuticals Ltd , incorporated in 1981 and a global manufacturer and marketer of pharmaceutical products, reported strong financial results for Q2FY26.
Financial Highlights:
- Revenues increased 13.39% year-on-year to ₹2,270 crore from ₹2,002 crore.
- Total expenses rose 9.52% to ₹1,932 crore from ₹1,764 crore.
- Consolidated net profit grew 24.26% to ₹251 crore from ₹202 crore.
- Earnings per share improved 24.78% to ₹12.84 from ₹10.29.
Growth was driven by strong domestic and international sales, operational efficiency, a broad therapeutic portfolio, and strategic partnerships.
Outlook:
Emcure Pharmaceuticals Ltd focuses on expanding global footprint, innovative product launches, and enhancing manufacturing capabilities to sustain growth momentum.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,